Ethan M Basch1, Mark Scholz2, Johann S de Bono3, Nicholas Vogelzang4, Paul de Souza5, Gavin Marx6, Ulka Vaishampayan7, Saby George8, James K Schwarz9, Emmanuel S Antonarakis10, Joseph M O'Sullivan11, Arash Rezazadeh Kalebasty12, Kim N Chi13, Robert Dreicer14, Thomas E Hutson15, Amylou C Dueck16, Antonia V Bennett17, Erica Dayan18, Milan Mangeshkar19, Jaymes Holland19, Aaron L Weitzman19, Howard I Scher18. 1. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ebasch@med.unc.edu. 2. Prostate Oncology Specialists, Marina del Rey, CA, USA. 3. Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, England, UK. 4. Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. 5. Western Sydney University School of Medicine, Sydney, Australia. 6. Sydney Medical School, University of Sydney and Sydney Adventist Hospital, Wahroonga, Australia. 7. Karmanos Cancer Institute, Detroit, MI, USA. 8. Roswell Park Cancer Institute, Buffalo, NY, USA. 9. University of Nebraska Medical Center, Omaha, NE, USA. 10. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. 11. Belfast City Hospital, Belfast, Northern Ireland, UK. 12. Norton Cancer Institute, Louisville, KY, USA. 13. British Columbia Cancer Agency, Vancouver, BC, Canada. 14. Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA, USA. 15. Texas Oncology Sammons Cancer Center, Dallas, TX, USA. 16. Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. 17. Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. 18. Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 19. Exelixis, Inc., Alameda, CA, USA.
Abstract
BACKGROUND:Bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) are associated with debilitating pain and functional compromise. OBJECTIVE: To compare pain palliation as the primary endpoint for cabozantinib versus mitoxantrone-prednisone in men with mCRPC and symptomatic bone metastases using patient-reported outcome measures. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind phase 3 trial (COMET-2; NCT01522443) in men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment withdocetaxel and either abiraterone or enzalutamide. INTERVENTION: Cabozantinib 60mg once daily orally versus mitoxantrone 12mg/m2 every 3wk plus prednisone 5mg twice daily orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was pain response at week 6 confirmed at week 12 (≥30% decrease from baseline in patient-reported average daily worst pain score via the Brief Pain Inventory without increased narcotic use). The planned sample size was 246 to achieve ≥90% power. RESULTS AND LIMITATIONS: Enrollment was terminated early because cabozantinib did not demonstrate a survival benefit in the companion COMET-1 trial. At study closure, 119 participants were randomized (cabozantinib: N=61; mitoxantrone-prednisone: N=58). Complete pain and narcotic use data were available at baseline, week 6, and week 12 for 73/106 (69%) patients. There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8). Barriers to accrual included pretreatment requirements for a washout period of prior anticancer therapy and a narcotic optimization period to maximize analgesic dosing. CONCLUSIONS: Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases. Future pain-palliation trials should incorporate briefer timelines from enrollment to treatment initiation. PATIENT SUMMARY: Cabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases.
RCT Entities:
BACKGROUND:Bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) are associated with debilitating pain and functional compromise. OBJECTIVE: To compare pain palliation as the primary endpoint for cabozantinib versus mitoxantrone-prednisone in men with mCRPC and symptomatic bone metastases using patient-reported outcome measures. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind phase 3 trial (COMET-2; NCT01522443) in men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with docetaxel and either abiraterone or enzalutamide. INTERVENTION: Cabozantinib 60mg once daily orally versus mitoxantrone 12mg/m2 every 3wk plus prednisone 5mg twice daily orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was pain response at week 6 confirmed at week 12 (≥30% decrease from baseline in patient-reported average daily worst pain score via the Brief Pain Inventory without increased narcotic use). The planned sample size was 246 to achieve ≥90% power. RESULTS AND LIMITATIONS: Enrollment was terminated early because cabozantinib did not demonstrate a survival benefit in the companion COMET-1 trial. At study closure, 119 participants were randomized (cabozantinib: N=61; mitoxantrone-prednisone: N=58). Complete pain and narcotic use data were available at baseline, week 6, and week 12 for 73/106 (69%) patients. There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8). Barriers to accrual included pretreatment requirements for a washout period of prior anticancer therapy and a narcotic optimization period to maximize analgesic dosing. CONCLUSIONS:Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases. Future pain-palliation trials should incorporate briefer timelines from enrollment to treatment initiation. PATIENT SUMMARY:Cabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases.
Authors: Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Matthew S Brown; Gregory H Chu; Hyun J Kim; Martin Allen-Auerbach; Cheryce Poon; Juliette Bridges; Adria Vidovic; Bharath Ramakrishna; Judy Ho; Michael J Morris; Steven M Larson; Howard I Scher; Jonathan G Goldin Journal: Nucl Med Commun Date: 2012-04 Impact factor: 1.690
Authors: Ethan Basch; Karen A Autio; Matthew R Smith; Antonia V Bennett; Aaron L Weitzman; Christian Scheffold; Christopher Sweeney; Dana E Rathkopf; David C Smith; Daniel J George; Celestia S Higano; Andrea L Harzstark; A Oliver Sartor; Michael S Gordon; Nicholas J Vogelzang; Johann S de Bono; Naomi B Haas; Paul G Corn; Frauke Schimmoller; Howard I Scher Journal: Eur Urol Date: 2014-02-20 Impact factor: 20.096
Authors: F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly Journal: Mol Cancer Ther Date: 2011-09-16 Impact factor: 6.261
Authors: David C Smith; Matthew R Smith; Christopher Sweeney; Aymen A Elfiky; Christopher Logothetis; Paul G Corn; Nicholas J Vogelzang; Eric J Small; Andrea L Harzstark; Michael S Gordon; Ulka N Vaishampayan; Naomi B Haas; Alexander I Spira; Primo N Lara; Chia-Chi Lin; Sandy Srinivas; Avishay Sella; Patrick Schöffski; Christian Scheffold; Aaron L Weitzman; Maha Hussain Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Ethan Basch; Karen Autio; Charles J Ryan; Peter Mulders; Neal Shore; Thian Kheoh; Karim Fizazi; Christopher J Logothetis; Dana Rathkopf; Matthew R Smith; Paul N Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L Meyers; Arturo Molina; Charles Cleeland Journal: Lancet Oncol Date: 2013-09-25 Impact factor: 41.316
Authors: P W Kantoff; S Halabi; M Conaway; J Picus; J Kirshner; V Hars; D Trump; E P Winer; N J Vogelzang Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Yohann Loriot; Kurt Miller; Cora N Sternberg; Karim Fizazi; Johann S De Bono; Simon Chowdhury; Celestia S Higano; Sarah Noonberg; Stefan Holmstrom; Harry Mansbach; Frank G Perabo; De Phung; Cristina Ivanescu; Konstantina Skaltsa; Tomasz M Beer; Bertrand Tombal Journal: Lancet Oncol Date: 2015-04-14 Impact factor: 41.316
Authors: C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor Journal: N Engl J Med Date: 2013-07-18 Impact factor: 91.245
Authors: Matthew R Smith; Christopher J Sweeney; Paul G Corn; Dana E Rathkopf; David C Smith; Maha Hussain; Daniel J George; Celestia S Higano; Andrea L Harzstark; A Oliver Sartor; Nicholas J Vogelzang; Michael S Gordon; Johann S de Bono; Naomi B Haas; Christopher J Logothetis; Aymen Elfiky; Christian Scheffold; A Douglas Laird; Frauke Schimmoller; Ethan M Basch; Howard I Scher Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544
Authors: Pablo Maroto; Camillo Porta; Jaume Capdevila; Andrea B Apolo; Santiago Viteri; Cristina Rodriguez-Antona; Lidia Martin; Daniel Castellano Journal: Ther Adv Med Oncol Date: 2022-07-13 Impact factor: 5.485
Authors: Halena R VanDeusen; Johnny R Ramroop; Katherine L Morel; Song Yi Bae; Anjali V Sheahan; Zoi Sychev; Nathan A Lau; Larry C Cheng; Victor M Tan; Zhen Li; Ashley Petersen; John K Lee; Jung Wook Park; Rendong Yang; Justin H Hwang; Ilsa Coleman; Owen N Witte; Colm Morrissey; Eva Corey; Peter S Nelson; Leigh Ellis; Justin M Drake Journal: Mol Cancer Res Date: 2020-05-27 Impact factor: 5.852
Authors: Ethan Basch; Claus Becker; Lauren J Rogak; Deborah Schrag; Bryce B Reeve; Patricia Spears; Mary Lou Smith; Mrinal M Gounder; Michelle R Mahoney; Gary K Schwartz; Antonia V Bennett; Tito R Mendoza; Charles S Cleeland; Jeff A Sloan; Deborah Watkins Bruner; Gisela Schwab; Thomas M Atkinson; Gita Thanarajasingam; Monica M Bertagnolli; Amylou C Dueck Journal: Clin Trials Date: 2020-12-01 Impact factor: 2.486
Authors: Ravi A Madan; Fatima H Karzai; Munjid Al Harthy; Daniel P Petrylak; Joseph W Kim; Philip M Arlen; Inger Rosner; Marc R Theoret; Lisa Cordes; Marijo Bilusic; Cody J Peer; Nancy A Dawson; Anna Couvillon; Amy Hankin; Moniquea Williams; Guin Chun; Helen Owens; Jennifer L Marte; Min-Jung Lee; Yusuke Tomita; Akira Yuno; Jane B Trepel; Sunmin Lee; Seth M Steinberg; James L Gulley; William D Figg; William L Dahut Journal: BJU Int Date: 2020-10-23 Impact factor: 5.969
Authors: Tianhong Pan; Mariane Martinez; Kelsea M Hubka; Jian H Song; Song-Chang Lin; Guoyu Yu; Yu-Chen Lee; Gary E Gallick; Shi-Ming Tu; Daniel A Harrington; Mary C Farach-Carson; Sue-Hwa Lin; Robert L Satcher Journal: Mol Cancer Ther Date: 2020-03-27 Impact factor: 6.009